Shuttle Pharmaceuticals Holdings, Inc. (SHPH) company profile
Close on Nov 13, 2026Market cap $4.54MP/E –Yield –
About Shuttle Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Shuttle Pharmaceuticals Holdings, Inc. operates as a pharmaceutical software and drug discovery enterprise centered around Molecule.ai, an artificial intelligence platform acquired in November 2025. The company previously developed clinical-stage therapeutic candidates, notably Ropidoxuridine, prior to initiating a wind-down of its clinical trials. Molecule.ai integrates a unified inference engine, an API-first framework, and modular predictive models to support molecular property prediction, multi-compound comparative analysis, and structured scientific reasoning. These software solutions serve researchers and pharmaceutical research and development teams navigating chemical exploration and early-stage drug design.
The business operates with two full-time employees. Its principal executive offices are situated in Gaithersburg, Maryland, United States. Corporate activities and research infrastructure center around this domestic headquarters location.
Summary of the business section of Shuttle Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Shuttle Pharmaceuticals Holdings, Inc.
- Founded
- 2012
- Headquarters
- Gaithersburg, MD
- Address
- 401 Professional Drive, Suite 260 20879
- Phone
- (240) 403-4212
- Website
- shuttlepharma.com
- Employees
- 2, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Forvis Mazars, LLP, Atlanta, Georgia
Stock & identifiers
- Ticker
- SHPH
- Exchange
- Nasdaq
- IPO date
- Aug 31, 2022
- Shares outstanding
- 5M, Sep 21, 2026
- Public float
- $4.74M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-10 reverse, Jun 11, 2026; 1-for-25 reverse, Jun 16, 2025; 1-for-8 reverse, Aug 13, 2024
- SEC CIK
- 1757499
- CUSIP
- 825693500
- ISIN
- US8256935003
- FIGI
- BBG017Z2NFJ1
- Share class FIGI
- BBG017Z2NGC6
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ryan Trasolini | Co-Chief Executive Officer | – |
| Yuying Liang | Chief Financial Officer | – |
| Timothy J. Lorber | Chief Financial Officer | 227,635 |
| Chris Cooper | Interim Co-CEO | – |
| Angel Liriano | Director | 0 |
| Arachchige Sachin Eranga Pathigoda | Director | 0 |
| Adam V. Chambers | Director | 0 |
| Steven M. Richards | Director | 210,004 |
| Joseph Tung | Director | 184,162 |
| George Scorsis | Director | 184,162 |
| Oleh Nabyt | Director | 184,162 |
| Joshua Schafer | Director | 210,004 |
| Milton Brown | Director | 346,617 |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Aug 31, 2022
- Offer price
- $8.13
- Securities offered
- 1,225,888
- Gross proceeds
- $9.96M
- Exchange
- Nasdaq
- First trading day
- Aug 31, 2022
- First-day close
- $38.48+373.6%
- Lock-up ends (est.)
- Feb 27, 2023
“The units are being offered at an assumed combined public offering price of $8.125 per unit and a combined effective offering price of $8.115 per share of common stock and an offering price of $0.01 for each warrant.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of the date of this Annual Report, we have two full-time employees.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?